Form 4: Halozyme COO Reports RSU Vesting and Tax-Related Stock Sale
Insider Transaction Report
Halozyme Therapeutics' COO, Cortney Caudill, reported the vesting of restricted stock units and subsequent sale of shares for tax obligations.
Summary
- Cortney Caudill, SVP, Chief Operating Officer of Halozyme Therapeutics, Inc. (HALO), reported transactions on November 1, 2025.
- Caudill acquired 9,326 shares of common stock through the vesting and settlement of restricted stock units (RSUs).
- Concurrently, 4,263 shares of common stock were disposed of at a price of $65.19 per share to satisfy tax withholding obligations.
- Following these transactions, Caudill directly beneficially owns 12,737 shares of common stock.
- Additionally, 18,651 derivative restricted stock units are beneficially owned directly.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The vesting of restricted stock units is a positive event for the executive as part of their compensation, reflecting continued alignment with shareholder interests. The subsequent sale for tax purposes is a routine, non-discretionary event and does not indicate a change in sentiment towards the company.
Positives
- The vesting of 9,326 restricted stock units indicates a component of executive compensation and retention, aligning management's interests with shareholders.
Negatives
- A disposition of 4,263 shares of common stock occurred, reducing direct beneficial ownership, although this was for tax withholding purposes.
Future Outlook
NA
Industry Context
This filing is a routine insider transaction report and does not provide specific insights into broader industry trends or competitive landscape for Halozyme Therapeutics.
Stakeholder Impact
- Shareholders: Provides transparency on executive compensation and stock ownership, which can influence investor confidence in management alignment.
- Employees: Reflects standard executive compensation practices, which may set precedents or expectations for other employees with equity awards.
Key Dates
| Date | Description |
|---|---|
| 11/01/2025 | Date of reported transactions, including RSU vesting and stock disposition. |
| 12/19/2025 | Date the Form 4 was signed by the attorney-in-fact. |
Keywords
HALO, Halozyme Therapeutics, Cortney Caudill, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Stock Sale, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.